The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000266369p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
2/02/2026
Date registered
Help: Date registered
3/03/2026
Date last updated
Help: Date last updated
3/03/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/03/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Ketamine for Post Traumatic Stress Disorder (PTSD): Feasibility and patient experience
Scientific title
Ketamine for Post Traumatic Stress Disorder (PTSD): Feasibility and patient experience
Additional trial identifiers [1] 316402 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
PTSD 340494 0
Condition category
Condition code
Mental Health 336701 336701 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
In the present study we propose investigating the feasibility of the use of a particular oral Ketamine (Ketalar® active ingredient: Ketamine hydrochloride). Dosing regimen with start with 5 consecutive days of stepwise increases of oral Ketamine from .5 to 2mg/kg (for example .5mg/kg for 1 day, 1mg/kg for 2 days, 1.5mg/kg for 1 day and 2mg/kg for 1 day) as tolerated; then 2mg/kg twice weekly for a further 10 weeks. The oral ketamine will be sipped with orange juice over a period of an hour under the supervision of research staff. The aim is to reduce PTSD symptoms in a population currently experiencing moderate to severe PTSD.
Intervention code [1] 333062 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344210 0
PTSD symptomology
Timepoint [1] 344210 0
Baseline (Week 1: screening), weekly during dosing (Weeks 2-11), end of trial (Week 12), weekly phone follow-ups for a further 8 weeks (Weeks 13-20) and final follow-up phone call at Week 23.
Primary outcome [2] 344211 0
Subjective experience of oral ketamine dosing schedule and study protocol
Timepoint [2] 344211 0
End of intervention (week 12)
Secondary outcome [1] 457091 0
Dissociation
Timepoint [1] 457091 0
Pre-and post-dose at every oral ketamine dosing session

Eligibility
Key inclusion criteria
To be included in the study, participants must meet all the following inclusion criteria:
1. Adult between 18 and 50 years of age.
2. Capable of understanding and signing an informed consent.
3. Have experienced a traumatic event and currently meet criteria for moderate-severe PTSD: a score of greater than or equals to 23 on the PTSD Symptom Scale Interview for DSM-5 (PSSI-5).
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
To be included in the study, participants must meet none of the following exclusion criteria:
1. Evidence of severe acute or chronic medical disorders.
2. Past or current diagnoses of schizophrenia, bipolar disorder, or current psychotic symptoms.
3. Current diagnosis of severe personality disorder.
4. Be pregnant or lactating.
5. Had drug abuse or dependence in the last 6 months.
6. Screening suggests that primary motivation for involvement in the study is seeking access to ketamine.
7. current significant suicidal ideation.
8. participants must be free of recreational drug and alcohol use at the time of testing.
9. Are under current psychotherapy treatment for PTSD.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 27787 0
New Zealand
State/province [1] 27787 0
Dunedin

Funding & Sponsors
Funding source category [1] 321012 0
Charities/Societies/Foundations
Name [1] 321012 0
Healthcare Otago Charitable Trust
Country [1] 321012 0
New Zealand
Primary sponsor type
University
Name
University of Otago
Address
Country
New Zealand
Secondary sponsor category [1] 323716 0
Government body
Name [1] 323716 0
Health New Zealand, Te Whatu Ora - Southern
Address [1] 323716 0
Country [1] 323716 0
New Zealand

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319544 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 319544 0
Ethics committee country [1] 319544 0
New Zealand
Date submitted for ethics approval [1] 319544 0
29/01/2026
Approval date [1] 319544 0
Ethics approval number [1] 319544 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147674 0
A/Prof Tess Patterson
Address 147674 0
Department of Psychological Medicine, Faculty of Medicine - Dunedin, University of Otago, PO Box 56, Dunedin, 9054
Country 147674 0
New Zealand
Phone 147674 0
+64 21 2791727
Fax 147674 0
Email 147674 0
Contact person for public queries
Name 147675 0
Tess Patterson
Address 147675 0
Department of Psychological Medicine, Faculty of Medicine - Dunedin, University of Otago, PO Box 56, Dunedin, 9054
Country 147675 0
New Zealand
Phone 147675 0
+64 21 2791727
Fax 147675 0
Email 147675 0
Contact person for scientific queries
Name 147676 0
Tess Patterson
Address 147676 0
Department of Psychological Medicine, Faculty of Medicine - Dunedin, University of Otago, PO Box 56, Dunedin, 9054
Country 147676 0
New Zealand
Phone 147676 0
+64 21 2791727
Fax 147676 0
Email 147676 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.